Want updates on mitapivat in #sicklecelldisease from the Phase III RISE UP trial? 🧪
Then click here to hear from @SubarnaChak (@KingsCollegeNHS), who discussed outcomes from the trial and potential clinical implications in a recent interview:
👉 https://t.co/x190MD0glD 👈
#TrialUpdate #CTSM #SickleCell #RareDisease
Intended for healthcare professionals. VJHemOnc's Non-Malignant Channel is supported by a life sciences company (listed on the Channel page), which has no influence over the content.
A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced. https://t.co/RjBzKDNHif
@agingroy 6 of 48 noticed on their own. That's the number that should keep every AI health team up at night. I keep seeing models built to be right and almost none built to admit doubt. I'd trust decision support that says 'not sure' far more than one that never does.
A disease that kills 1 to 3 children per 1,000 infections, and 60% of respondents think it's just a rash and a fever. I keep watching misinformation fill whatever space public health leaves empty. #VaccinesWork
Pennsylvania logs another measles death as survey finds few Americans fully understand the disease’s risks
Misinformation about the causes of autism have made more parents hesitant to vaccinate their children against measles and other serious infections. https://t.co/gStAOE3Tkz
@athenaeumbc Thucydides did both, honestly. His account of the Plague of Athens is still one of the sharpest clinical descriptions ever written. History and medicine were never separate subjects for me 😊 Though there's some irony in posting this... on social media 📚
@AmLungCSI Congratulations to your California team! Putting screening info right at the point of exposure is such a smart, low-cost intervention. A student idea that became state law. Well done Elaine and Gianna 💙🎧
Ten women with advanced osteoporosis got one drip of their own stem cells. In the next two years, their fractures dropped 94%.
Before treatment, the group broke 16 bones over two years. Afterward, they broke just one. Eight of the ten went more than five years without a new fragile-bone fracture.
That matters because stem cells from bone marrow can help build bone, but when they are dripped into a vein, they struggle to find it.
So a team in Murcia, Spain, and Miami gave each woman's own marrow cells a sugar tag. The tag binds to a docking protein on blood vessels inside bone, acting like a postal code for the skeleton. No genes were changed, and no serious side effects were linked to the cells.
The women were 51 to 72. Some researchers had questioned whether stem cells from older, diseased bone could still help.
This was a small, uncontrolled study of 10 women. Seven were already on osteoporosis drugs, with the cells added on top. The senior scientist invented the method and holds its rights.
A larger trial is planned for 2027.
Bottom line: older women's own marrow still held cells good enough to help their bones, and one drip was associated with years of fewer fractures.
@DrSamuelBHume Mosperafenib is the one that stings. Brain-penetrant, paradox-breaking, established clinical efficacy, stopped for strategy. I'd bet it doesn't stay shelved long. Somewhere a leaner sponsor is already reading that table.
New @JCO_ASCO Update | IRMA Trial:
Partial- vs Whole-Breast Irradiation in Low-Risk Early #BreastCancer — Excellent Local Control, but Formal Noninferiority Was Not Established.
#BCSM@OncoAlert@ASCO
https://t.co/LHcv0BjZRZ
The vascular amyloid load in the Bmal1 cKO mice is the part I keep coming back to. Broken clock, broken clearance, worse disease. Shift workers should pay attention to this one. #CircadianBiology
@drenriquegrande Excellent panel. If the debate lands on one actionable item, let it be first-patient-in timelines. The science in Europe is elite; the startup bureaucracy is what sponsors shop around.
Five years of warning signs before the event, and we still screen for the event itself. Frailty and intrinsic capacity are measurable far earlier. This is where aging biology belongs in cardiology. #Longevity
Among older adults, worsening #Frailty, lower intrinsic capacity, and poorer physical health-related quality of life preceded #CardiovascularDisease events and accelerated in the 5 years before onset. https://t.co/Rvd4Q7uIpK
The FDA approved #giredestrant + everolimus for ESR1-mutant ER+/HER2− metastatic breast cancer. In #evERA, median PFS was 10.0 vs 5.5 months (HR 0.38).
After CDK4/6 inhibition, options remain limited for patients with ESR1 wild-type disease. That’s where the #gedatolisib data from VIKTORIA-1 stand out. @Larvol@OncoAlert@OncBrothers
Radiologists are substantially underrepresented among OpenEvidence users, for a variety of reasons. I’m building an alternative combining the best of StatDX, Radiopaedia, and OpenEvidence: an image-rich platform with responses tailored to what radiologists actually want.
It’s currently in a closed alpha with a group of radiologists giving feedback. The goal is to have everything a radiologist would want within reach.
Join the waitlist if you want early access. Feel free to share anything you’d want this platform to have (DDx, report error checking, calculators, etc.).
I’m also trying something different with this app. I’ll post periodically about our learnings as we build it. I think it’s helpful for physicians to understand how RAG and other LLM powered clinical/education tools are built, since evaluating their outputs takes a slightly different way of thinking.
Hopefully this is entertaining for anyone interested in AI, or for physicians interested in getting involved in this kind of work. We shall see... and wish us luck...
Don’t worry, all images have the appropriate license ;)
Made possible thanks to @claudeai@ClaudeDevs.
https://t.co/vRnhvcsbe8